Rodolphe Barrangou
Director/Board Member at Ancilia Biosciences, Inc.
Profile
Rodolphe Barrangou is the founder of Intellia Therapeutics, Inc. (founded in 2014) and Locus Biosciences, Inc. (founded in 2015).
He is currently a Director at Ancilia Biosciences, Inc. Dr. Barrangou was formerly the Chairman at Caribou Biosciences, Inc. Dr. Barrangou has a graduate and doctorate degree from North Carolina State University, an MBA from the University of Wisconsin, a graduate degree from Université de Technologie de Compiègne, and an undergraduate degree from Université de Paris 5 René Descartes.
Rodolphe Barrangou active positions
| Companies | Position | Start |
|---|---|---|
Ancilia Biosciences, Inc.
 Ancilia Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ancilia Biosciences, Inc. is an American company that is developing virus-resistant live bacterial biotherapeutics to alter the gut microbiome and treat disease. Ancilia is based in the United States, and its founders and advisers include key scientific leaders across CRISPR and the virome. Ancilia's proprietary platform is being developed as an essential enabling technology that characterizes viral phages and leverages the natural function of CRISPR to produce a new class of live biotherapeutics with engineered immunity to key viral pathogens. The company has demonstrated proof of principle and filed key patents for the technology. The company was founded to overcome a potential obstacle to the success of LBPs, which is their failure to address the role of predatory viral phages in causing disease and limiting the ability of LBPs to engraft in the gut. The company was founded by Alexandra Sakatos, who has been the CEO since incorporation. | Director/Board Member | - |
Former positions of Rodolphe Barrangou
| Companies | Position | End |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Chairman | - |
Locus Biosciences, Inc.
 Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Founder | - |
| INTELLIA THERAPEUTICS, INC. | Founder | - |
Training of Rodolphe Barrangou
| North Carolina State University | Doctorate Degree |
| University of Wisconsin | Masters Business Admin |
| Université de Technologie de Compiègne | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Université de Paris 5 René Descartes | Consumer Services |
Locus Biosciences, Inc.
Locus Biosciences, Inc. Packaged SoftwareTechnology Services Locus Biosciences, Inc. develops CRISPR-engineered precision antibacterial products for antibiotic-resistant bacterial infections and microbiome-related disease. The firm offers CRISPR-engineered bacteriophage and CRISPR-Cas3 phage. The company was founded by Charles Gersbach, Dave Ousterout, Chase Beisel, Paul M. Garofolo, Nick Taylor, and Rodolphe Barrangou in 2015 and is headquartered in Morrisville, NC. | Technology Services |
Ancilia Biosciences, Inc.
Ancilia Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Ancilia Biosciences, Inc. is an American company that is developing virus-resistant live bacterial biotherapeutics to alter the gut microbiome and treat disease. Ancilia is based in the United States, and its founders and advisers include key scientific leaders across CRISPR and the virome. Ancilia's proprietary platform is being developed as an essential enabling technology that characterizes viral phages and leverages the natural function of CRISPR to produce a new class of live biotherapeutics with engineered immunity to key viral pathogens. The company has demonstrated proof of principle and filed key patents for the technology. The company was founded to overcome a potential obstacle to the success of LBPs, which is their failure to address the role of predatory viral phages in causing disease and limiting the ability of LBPs to engraft in the gut. The company was founded by Alexandra Sakatos, who has been the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- Rodolphe Barrangou
